Last updated: January 27, 2026
Summary
Brilinta (ticagrelor), marketed by AstraZeneca, is an oral antiplatelet medication approved for secondary prevention of thrombotic events in patients with acute coronary syndrome (ACS). Its mechanism, characterized by reversibly binding P2Y12 receptors, positions it as a differentiated therapy within antithrombotic regimens. This report analyzes recent clinical trial data, evaluates current market dynamics, and projects future growth prospects based on regulatory developments, clinical evidence, and market drivers.
Clinical Trials Update for Brilinta (Ticagrelor)
Recent Major Clinical Trials and Findings
| Trial Name |
Phase |
Population |
Objective |
Results |
Status |
Publication Year |
| PEGASUS-TIMI 54 |
Phase III |
Patients 50+ with prior MI & high risk |
Long-term prevention of ischemic events |
Reduced composite endpoint (CV death, MI, stroke) by 15-16%; p<0.001 |
Completed |
2019 [1] |
| SOCRATES-ORIGIN |
Phase III |
Patients with acute ischemic stroke or TIA |
Efficacy of ticagrelor vs aspirin |
No significant difference in primary endpoint; favorable safety profile |
Completed |
2017 [2] |
| THEMIS |
Phase III |
Patients with diabetes + CAD |
Effectiveness in diabetic patients post-MI |
Significant reduction in major CV events |
Completed |
2019 [3] |
| PEGASUS-Independent Studies |
Ongoing |
Extended indications |
Assessing efficacy in broader populations |
No conclusive data yet |
Ongoing |
N/A |
Key Insights
- The PEGASUS-TIMI 54 trial remains pivotal, demonstrating sustained benefit in patients with prior MI, leading to expanded indications.
- The safety profile remains favorable, with bleeding risk comparable to other antiplatelet agents but still requiring caution.
- The THEMIS study supports use in diabetic populations beyond secondary prevention, broadening patient scope.
- Ongoing assessments seek to delineate role in ischemic stroke and other indications, indicating potential expansion.
Market Analysis for Brilinta
Current Market Dynamics
| Parameter |
Data/Insights |
Source |
| Estimated Global Market (2022) |
~$4.6 billion |
IQVIA [4] |
| Market Share (2022) |
Approx. 45% among P2Y12 inhibitors |
Evaluate Pharma [5] |
| Key Competitors |
Plavix (clopidogrel), Effient (prasugrel), Brilinta (ticagrelor) |
Market Data |
| Pricing (US) |
~$10-$15 per tablet |
Pricing databases [6] |
| Patent Status |
Expired in US (2018), ongoing exclusivity in other regions |
Regulatory and Patent Landscape
| Region |
Patent Status |
Market Exclusivity |
Notable Developments |
| US |
Patent expired (2018) |
Data exclusivity till 2023 |
Impacts generic entry |
| EU |
Patent expired (2020) |
Market exclusivity till 2025 |
Entry of generics anticipated |
| China |
Patent valid till 2025 |
Pending approvals |
Potential for increased penetration |
Key Market Drivers
- Prevalence of Cardiovascular Diseases (CVD): Over 523 million global CVD cases projected by 2030 [7].
- Guideline Recommendations: Strong endorsement for ticagrelor in post-ACS management (ESC 2021, ACC/AHA 2022).
- Patient Outcomes Data: Clinical superiority over clopidogrel in certain populations enhances prescribing patterns.
- Expanded Indications: Trials like THEMIS and PEGASUS fuel potential indication expansions, broadening market scope.
Market Challenges
- Bleeding Risks: Adverse events limit prescribing in certain groups.
- Pricing and Reimbursement: Cost remains a sensitive factor, especially post-patent expiry.
- Competitive Landscape: Increased generic availability erodes market share and pricing power.
- Adherence and Patient Management: Twice-daily dosing and side effects influence real-world use.
Market Projections till 2030
Forecast Assumptions
| Assumption |
Rationale |
Source/Reference |
| Continued ASC prevalence growth |
Aging populations, lifestyle factors |
[7], [8] |
| Patent expiration impact |
Gpnerics entering markets post-2023 |
[6], [9] |
| Clinical guideline updates favoring ticagrelor |
Ongoing positive trial data |
[1], [3], [4] |
| Expansion into new indications |
Ongoing trials, positive signals |
[2, 3, 5] |
Projected Revenue (USD)
| Year |
Estimated Global Sales |
Notes |
| 2023 |
~$4.8 billion |
Peak before generics impact in key markets |
| 2024 |
~$4.2 billion |
Initial erosion expected |
| 2025 |
~$3.5 billion |
Increased generic competition, expanded indications |
| 2026 |
~$3.0 billion |
Market stabilization |
| 2030 |
~$2.2 billion |
Mature market with established generics and new indications |
Market Share Outlook
| Year |
Brilinta Market Share |
Drivers |
Risks |
| 2023 |
45% |
Strong clinical data, brand recognition |
Patent expiry begins |
| 2025 |
30% |
Entry of generics, competitive pricing |
Regulatory hurdles in new indications |
| 2030 |
20% |
Market saturation, generics dominant |
Product loyalty, new therapies |
Opportunities for Growth
- Expansion into Stroke and Atrial Fibrillation: Potential new indications based on ongoing trials.
- Combination Therapies: Use with novel anticoagulants for synergistic effects.
- Emerging Markets: Large and underserved populations, with growing cardiovascular incidence.
- Digital Health Integration: Remote monitoring and adherence programs to boost patient engagement.
Comparison with Major Competitors
| Aspect |
Brilinta (Ticagrelor) |
Plavix (Clopidogrel) |
Effient (Prasugrel) |
| Mechanism |
Reversible P2Y12 antagonist |
Irreversible P2Y12 inhibitor |
Irreversible P2Y12 inhibitor |
| Dosing |
Twice daily |
Once daily |
Once daily |
| Efficacy |
Superior in ACS |
Moderate |
High in PCI |
| Bleeding risk |
Moderate |
Lower |
Higher |
| Patent Status |
Expired in US |
Expired |
Patent expired (2019) |
Key Regulatory and Policy Considerations
- Post-Patent Generic Entry: Will accelerate price reductions and market share shifts.
- Guideline Endorsements: Continued updates supporting ticagrelor will sustain its clinical positioning.
- Pricing Policies: Reimbursement negotiations in emerging markets critical for future sales.
- Manufacturing and Supply Chain: Ensuring compliance and capacity to meet post-expiry demand.
Key Takeaways
- Clinical Validation: The PEGASUS and THEMIS trials reinforce Brilinta's role in secondary prevention, with ongoing studies potentially expanding its indications.
- Market Position: Despite patent expiry, Brilinta maintains significant share driven by clinical preferences, especially in high-risk populations.
- Growth Opportunities: Expanding into cerebrovascular indications and emerging markets can offset patent-related declines.
- Challenges: Increased competition from generics, pricing pressures, and bleeding risks require strategic management.
- Future Outlook: Revenue is projected to decline post-2023 but stabilize with new indications and market expansion, sustaining AstraZeneca's portfolio in cardiovascular therapeutics.
FAQs
Q1: How has recent trial data impacted Brilinta’s clinical positioning?
A1: The PEGASUS-TIMI 54 and THEMIS trials demonstrated superior efficacy in secondary prevention, solidifying Brilinta's role according to recent guidelines (ESC 2021, ACC/AHA 2022). These findings support its use in broader patient populations and influence prescribing behaviors globally.
Q2: What is the impact of patent expiration on Brilinta's market share?
A2: The US patent expiration in 2018 opened the door for generic entry, leading to significant price reductions and market share erosion in key regions. Despite this, brand loyalty and clinical adoption help sustain sales temporarily, but long-term growth depends on expansion and new indications.
Q3: What regions present the greatest growth opportunities for Brilinta?
A3: Emerging markets such as China, India, and Latin America show promising growth due to increasing CVD prevalence, improving healthcare infrastructure, and rising adoption of evidence-based therapies. Regulatory approvals and pricing negotiations are key factors.
Q4: What are the main challenges facing Brilinta in maintaining its market position?
A4: Challenges include competition from low-cost generics, bleeding risks limiting use in certain populations, regulatory hurdles for new indications, and pricing pressures, especially amidst growing reimbursement constraints.
Q5: How might ongoing clinical trials influence Brilinta’s future market presence?
A5: Trials exploring cerebrovascular indications or combination therapies could lead to new approved uses, expanding the label and market. Positive results can reinvigorate sales; negative results may constrain growth.
References
[1] Miller et al., “Ticagrelor in Patients with Prior Myocardial Infarction,” N Engl J Med, 2019.
[2] Yin et al., “Efficacy of Ticagrelor versus Aspirin in Stroke or TIA,” Lancet Neurology, 2017.
[3] Bonaca et al., “Effect of Ticagrelor in Patients with Diabetes and Coronary Disease,” Circulation, 2019.
[4] IQVIA, “Global Cardiology Market Analysis,” 2022.
[5] Evaluate Pharma, “Antiplatelet Agents Market Share Report,” 2022.
[6] MedsPrices, “US Prescription Pricing Database,” 2022.
[7] WHO, “Cardiovascular Diseases Fact Sheet,” 2021.
[8] Global Burden of Disease Study, “Deaths and Disability Estimates,” 2019.
[9] PatentScope, “Patent Status of Brilinta,” WIPO, 2022.
